Rare FN1 Mutation Shields APOE-ε4 Carriers From Alzheimer’s by Preserving Blood-Brain Barrier

Scientists at Columbia University Irving Medical Center have pinpointed a rare protective mutation in the FN1 gene that curtails fibronectin buildup around brain blood vessels, thereby maintaining blood-brain barrier integrity in carriers of the APOE-ε4 allele, the strongest common genetic risk factor for Alzheimer’s. Using human brain samples, cerebrospinal fluid, single-cell sequencing, and animal models, the researchers demonstrated that APOE-ε4 drives excess fibronectin, which activates integrin-FAK pathways and disrupts VEGF-related growth-factor signaling, leading to barrier leakage.

Manipulating fibronectin levels in astrocytes directly altered barrier permeability, confirming causality. Human data corroborated these mechanisms, linking elevated fibronectin to vascular inflammation. The findings open avenues for therapies that block fibronectin accumulation or its downstream signals, though any intervention must avoid impairing fibronectin’s normal tissue-repair roles. This work provides a concrete target for preventing early vascular damage that precedes Alzheimer’s pathology.